SCHEMBL15082199

SCHEMBL15082199

C[C@@H](CCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.76
GAA P10253 1/20 0.76
KMT2A Q03164 1/20 0.76
TDP1 Q9NUW8 1/20 0.56
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
CA1 P00915 7/20 0.47
CA2 P00918 7/20 0.47
CA12 O43570 6/20 0.47
CA9 Q16790 6/20 0.47
STK17B O94768 1/20 0.42
STK17A Q9UEE5 1/20 0.42
BLM P54132 1/20 0.41
CTSS P25774 2/20 0.40
CTSK P43235 2/20 0.40
EPHX1 P07099 1/20 0.40
HTT P42858 1/20 0.40
CAPN1 P07384 1/20 0.39
CA7 P43166 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23417829 1.00 MEN1 (0.76) MEN1GAAKMT2ATDP1MAOA
SCHEMBL12571330 1.00 MEN1 (0.76) MEN1GAAKMT2ATDP1MAOA
SCHEMBL9945627 0.95 MEN1 (0.69) MEN1GAAKMT2ATDP1MAOA
SCHEMBL12762769 0.95 MEN1 (0.69) MEN1GAAKMT2ATDP1MAOA
SCHEMBL12787794 0.95 MEN1 (0.69) MEN1GAAKMT2ATDP1MAOA
SCHEMBL18251802 0.94 MEN1 (0.67) MEN1GAAKMT2ATDP1MAOA
SCHEMBL15723436 0.90 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
SCHEMBL45626 0.90 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
SCHEMBL7882078 0.90 MEN1 (0.65) MEN1GAAKMT2ATDP1MAOA
SCHEMBL16575053 0.90 MEN1 (0.61) MEN1GAAKMT2ATDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 US disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 US disclosed
EP-4129983-A1 CRYSTAL FORM OF NITROXOLINE PRODRUG, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2023-02-08 EP disclosed
WO-2019195159-A1 PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2019-10-10 WO disclosed
US-10039809-B2 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-08-07 US disclosed
US-10010589-B2 2018-07-03 US disclosed
US-9950993-B2 Bacterial efflux pump inhibitors RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2018-04-24 US disclosed
US-20160317623-A1 MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF THE SCRIPPS RESEARCH INSTITUTE 2016-11-03 US disclosed
US-20160271081-A1 BACTERIAL EFFLUX PUMP INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-09-22 US disclosed
WO-2016057413-A2 INHIBITORS OF LYSINE GINGIPAIN Cortexyme, Inc. (US) 2016-04-14 WO disclosed
US-20160017000-A1 RGD-CONTAINING CYCLIC PEPTIDES UNIV CALIFORNIA (US) 2016-01-21 US disclosed
US-9073974-B2 RGD-containing cyclic peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-07-07 US disclosed
US-20130172270-A1 RGD-CONTAINING CYCLIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160317623-A1 MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF SGMS1, SGMS2, PHOSPHO1 MEN1 25/4885GAA 852/4885KMT2A 3238/4885
US-10010589-B2 TYMP, MTAP, TUBB6 MEN1 426/4885GAA 870/4885KMT2A 3455/4885
US-20160271081-A1 BACTERIAL EFFLUX PUMP INHIBITORS ABCB11, ABCB1, SLC47A1 MEN1 4227/4885GAA 178/4885KMT2A 4731/4885
US-11795196-B2 Mitochondria-targeting peptides HSPE1, TFAM, TNNI3 MEN1 4795/4885GAA 1795/4885KMT2A 4820/4885
US-10039809-B2 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof SGMS1, SGMS2, PHOSPHO1 MEN1 25/4885GAA 852/4885KMT2A 3238/4885
US-20160017000-A1 RGD-CONTAINING CYCLIC PEPTIDES ITGAV, ITGB3, ITGAL MEN1 3074/4885GAA 3950/4885KMT2A 4670/4885
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 MEN1 4795/4885GAA 1795/4885KMT2A 4820/4885
US-20130172270-A1 RGD-CONTAINING CYCLIC PEPTIDES ITGAV, ITGB3, ITGAL MEN1 3074/4885GAA 3950/4885KMT2A 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.